|
Morria Biopharmaceuticals |
|
|
53 Davies street
Mayfair, London W1K5JH United Kingdom
phone:44 (0)207 152 6341
fax:44 (0) 207 152 6342 |
| Symbol |
Private |
| Founded |
0 |
| Employees |
|
|
|
| www.morria.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs. |
|
| Management |
| Dr. Yuval Cohen (CEO); Prof. Saul Yedgar (Chief Scientific Officer); Dr. Joe Bondi (CMC); Dr. Richard Serbin (Regulatory); Dr. Russ Middaugh (Advisor: Analytical Methods Development); Dr. Neil Ravenscroft (Advisor: Molecular Characterization); Dr. Jules Mitchel (PhD); Dr. Carl Osborn (DV); Drs (MD). Brian Leaker and Trevor Hansel |
|
|
| |
| Keywords |
| inflammatory, agents, drugs, mfaid, target, enzyme, pla2, inflammation, skin, lung, psoriasis, asthma, sepsis, dermatitis |
|
|
|
|
|
| Description |
|
Morria Biopharmaceuticals develops a propriety platform of novel anti-inflammatory agents termed Multi-Functional Anti-Inflammatory Drugs (MFAID). |
|
| Technology / Differentiation |
| The Multi-Functional Anti-Inflammatory Drugs (MFAID) target the extracellular enzyme PLA2, a key event in the inflammation process upstream of any current competitors and also protect cells and tissues against inflammatory damage and stimuli. |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members